Introduction
The development of proteasome inhibitors has been an outstanding case showing that irreversible inhibitors may provide unique advantages by forming long-lived ties with their target. [1] Depending on the degree of reversibility of this covalent interaction, the putative proteasome inhibitor may therefore display a prolonged interaction and therefore biological action. A prolonged interaction may be beneficial when the undesired proteasome activity is manifest for an extended period. [2, 3] Together with covalently reacting kinase inhibitors, which contain Michael acceptor moieties, proteasome inhibitors are part of the important arsenal of presently available crucial anti-cancer drugs. Inhibition of the protein degradation pathway in this manner is currently an effective approach for treatment of blood cancers. [4, 5] Increasingly, established proteasome inhibitors are evaluated as anti-inflammatory immunoproteasome inhibitors leading to new therapeutic strategies for treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis [6, 7] Recently, in collaboration with Groll et al., we have achieved selective inhibition of the immunoproteasome by crosslinking of the active site effected by a peptido sulfonyl fluoride ligand (PSF). [8] Most proteasome inhibitors contain a single electrophilic moiety capable of covalently interacting with the threonine active site residue. [9] For example, the Michael acceptor electrophile containing proteasome inhibitors, especially the vinyl sulfones containing ones have been subject of intense investigations (Scheme 1). [10] ***Rob, deze laatste zin vond reviewer 1 difficult to understand, dus moeten we herschrijven.*** Scheme 1. Mechanisms of covalent inhibition of the proteasome by vinyl sulfones, α-β-epoxyketones and α-ketoaldehydes. The threonine depicted in red represents the N-terminal threonine of the proteasome.
However, in contrast to serine proteases in which the attacking nucleophile on the peptide-amide bond is the hydroxyl of the serine residue present as part of the catalytic triad, in the proteasome the amino acid involved in scission of the peptide-amide bond is an N-terminal threonine residue. This N-terminal threonine residue contains two nucleophiles. As a consequence, very effective, and selective inhibition has been achieved by proteasome inhibitors having 'dual' warheads that is containing two electrophilic sites. This is reflected by the treatment of multiple myeloma in patients with the proteasome inhibitor carfilzomib containing both an epoxide and carbonyl electrophilic site, after previous treatment with bortezomib, which contains just one electrophilic site (Figure 1 ). In our opinion this justifies a quest for dual warhead containing inhibitors such as the one discussed in this research.
Scheme 2.
Mechanism of covalent inhibition of the proteasome by peptido sulfonyl fluorides (PSF) [8] and proposed mechanism for inhibition by peptido vinylsulfonyl fluorides (PVSF). The threonine depicted in red represents the N-terminal threonine of the proteasome. Inspired by the "dual' warhead approach we describe in this paper a new proteasome inhibitor concept in which a Michael electrophilic trap, is combined with a sulfonyl fluoride electrophile incorporated into a peptide sequence leading to a peptido vinylsulfonyl fluoride (PVSF). Both electrophilic traps may then interact with both nucleophilic amino and hydroxyl moieties, of the N-terminal threonine residue present in the active site of the proteasome. Other covalently interacting proteasome inhibitors, having two electrophilic sites including Epoxomicin (Figure 1 ) and the alpha keto-aldehyde warhead containing inhibitors, show a similar molecular mechanism of action (Scheme 1). [11, 12] However, in the sulfone Michael acceptor containing proteasome inhibitors only the 4-position is reacting with the threonine nucleophile(s) (Scheme 1).
Results and discussion

Chemistry
Here we propose the peptido vinylsulfonyl fluoride (PVSF) as a new and promising dual warhead system. It was expected that its molecular structure would allow a Michael reaction leading to a sulfene intermediate followed by an intramolecular reaction of the second nucleophile in the threonine residue leading to a seven-membered ring covalent adduct (Scheme 2).
The synthesis of peptido vinyl sulfonyl fluorides involved employing vinylogous amino sulfonates, which are accessible from amino acid derived aldehydes as was described by Gennari et al. (Scheme 3). [13] Briefly, Cbzprotected leucinol (2) was converted into the corresponding amino aldehyde (3) by a Swern oxidation. A Wittig-Horner reaction with ethyl diethylphosphoryl methanesulfonate afforded vinylsulfonate ester 6, which was cleaved by Bu4NI. The most efficient conversion of the resulting sulfonate salt (7) into the corresponding vinylsulfonyl fluoride (8) was achieved by using talFluor-M ® [14] in the presence of a catalytic amount of triethylamine trihydrofluoride acting as both a proton and fluoride source. [15] Two PVSF proteasome inhibitors (10 and 11, respectively) were obtained after cleavage of the Cbz-group from 8 followed by a coupling reaction with Cbz-Leu2-OH and Cbz-Leu3-OH using BOP. 
Biological evaluation
Recently, we described and established the molecular mechanism of action of our peptido sulfonyl fluoride (PSF) proteasome protease inhibitors. [8] It was found that selective inhibition of the immunoproteasome occurred by ligand-induced cross-linking of the active site (Scheme 2). With respect to this, comparison with other warheads highlights the peptido sulfonyl fluoride as a promising motif for 5i targeting. **hier iets zeggen dat de PSF ook erg goed werkt voor 5c, nu lijkt het dat dit niet zo is*** The sequences of inhibitors 10 and 11 were chosen based on earlier results with our most potent PSF proteasome inhibitors 17 and 18 (IC50-values 89 nM and 18 nM, respectively, Figure 2 ). [16] Evaluation of the proteasome inhibitory activity gave IC50-values of 218 nM and 99 nM for PVSF compounds 10 and 11, respectively (Figure 1 ). At first we were somewhat surprised by the diminished activity of the PVSF's as compared to PSF's 17 and 18, respectively. Although a PVSF may be more reactive than a PSF, the sulfonyl fluoride warhead part may occupy a less favourable P1' position because it is further positioned from the P1 side chain, leading a reduced inhibition. Therefore, we believe that by evaluating different amino acid sequences with the vinyl sulfonyl fluoride dual warhead, as was done with the sulfonyl fluoride warhead, [16] even lower IC50-values may be obtained. To investigate whether the proposed formation within the enzyme of a 7-membered ring adduct could be observed by chemo-synthesis, in parallel, the reactivity of a simplified peptido vinylsulfonyl fluoride (8) was studied with H-ThrVal-N(H)Me (13) as a model of the threonine residue present in the catalytic site of the proteasome (Scheme 4). Since formation of a seven membered-ring is not a very favourable reaction and the threonine residue is an ambidextrous nucleophile, an entirely clean reaction was not expected. In addition, other residues of the catalytic site of the proteasome are absent, especially any basic residues, which may affect the relative nucleophilicity of the threonine nucleophiles and thereby the sequence of steps in the molecular mechanism of inhibition by this PVSF warhead. + ions of the 7-membered ring containing molecule (13), (Scheme 4, for LCMS spectrum see supporting information) ***Rob evt. Meer uitleg hier ivm laatste punt reviewer 5*** we were unable to isolate this adduct after (silica gel) column chromatography and preparative HPLC. Attempts by varying the solvent (DCM or MeCN) of the reaction and base (DBU, Et3N or NMM) were also unsuccessful to increase product formation and subsequent isolation of a 7-membered ring structure. ***hier korte uitleg dat de gevonden massa ook de open ring had kunnen zijn indien een Thr1 nucleofiel de fluor substitueert, en dat dit niet voor de hand ligt omdat uit eigen bevindingen en uit de literatuur[17+18] blijkt dat bij vinyl sulfonyl fluoriden het nucleofiel altijd eerst aanvalt op de Michael acceptor. Indien het tweede nucleofiel niet zou aanvallen om de 7-ring te vormen, dan zou de open ring nog een sulfonyl fluoride of sulfonaat bij eventuele hydrolyse hebben, wat een andere massa zou hebben.*** Therefore, we felt that it was necessary to get some insight in the reactivity of the peptido vinylsulfonyl fluorides and to what extent the proposed -"in vivo", that is in the proteasome -7-membered ring might be formed "in vitro". Instead of the amino-group nucleophile as present in the threonine dipeptide model, the much simpler benzyl amine was used in excess. A disubstituted compound (16) resulting from a Michael reaction and substitution at the sulfonyl fluoride moiety was expected (Scheme 5). Unexpectedly, only traces of 16 were detected using ESI-MS, and instead -sultam 15 was formed. A plausible mechanism of formation is a Michael reaction followed by an intramolecular -sultam formation. Indeed -sultam compounds have been prepared conveniently in the past by reaction of ethenesulfonyl fluoride with various amines. [19] In agreement with the literature the first step is probably a Michael reaction of the amine (scheme 5). [18] Since a 7-membered ring is in general not easily accessible, its proposed formation in vivo may be challenging to mimic in vitro. Scheme 5. Reaction and proposed mechanism of β-sultam formation of vinylsulfonyl fluoride 8 with benzyl amine.
Conclusions
We have introduced a peptido vinylsulfonyl fluoride (PVSF) as a new dual warhead containing proteasome inhibitor, active in a concentration as low as 90 nM. In contrast to our recently described peptido sulfonyl fluoride inhibitors, (Scheme 2) in which the inhibitor is released from the proteasome leaving a crosslinked proteasome active site behind, the peptido vinylsulfonyl fluoride was proposed to give rise to the formation of a covalent 7-membered ring adduct. This adduct should result from reaction of both nucleophiles of the threonine active site residues with the electrophiles of the dual warhead. The presence of simultaneously two electrophilic sites, which can both react because of the "combined effort" of the nucleophiles in the proteasome threonine residue, might be beneficial for the selectivity of these novel proteasome inhibitors, which were somewhat less active than the earlier developed PSF's. Although there was an indication of formation of the proposed 7-membered ring structure we were unable to isolate it and achieve its synthesis "in vitro", which instead led to formation of a -sultam structure. To our knowledge, no other more complex unsaturated sulfonyl fluorides, similar to the ones, which are topic of this paper, have been described in the literature in reactions with nucleophiles leading to sultams. Clearly, elucidation of the mechanism of inhibition of the proteasome by these new dual warhead containing peptido vinyl sulfonyl fluorides awaits a crystallographic analysis of these inhibitors within the proteasome, which is an important aim for future research.
Experimental
All reagents were obtained from commercial sources and used without further purification. THF was distilled over LiAlH4. Petroleum ether used for column chromatography was the 40-60 °C fraction. Peptide grade and HPLC grade solvents were purchased from Actu-All (Oss, The Netherlands). Solvents were evaporated under reduced pressure at 40°C. The capping solution used was a mixture of 0.5 M acetic anhydride, 0.125 M DiPEA and 0.015 M HOBt in NMP. Reactions were carried out at ambient temperature unless stated otherwise. Reactions in solution were monitored by TLC analysis on Merck pre-coated silica gel 60 F-254 (0.25 mm) plates. Spots were visualised by UV light and by heating plates after dipping in a ninhydrine solution or in chlorine gas and TDM solution. [20] Column chromatography was performed on Siliaflash P60 (40-63 μm) from Silicycle (Canada).
1 H NMR data were acquired on a Varian Mercury 300 MHz spectrometer, an Agilent 400 MHz spectrometer or on Bruker Avance III 400 MHz and 500 MHz spectrometers in CDCl3, DMSO-d6 or acetone-d6 
Cbz-Leucinal (3)
To a stirred solution of oxalyl chloride (5.45 mL, 63.0 mmol) in CH2Cl2 (100 mL), under N2 atmosphere and cooled at -78 °C, were subsequently added dropwise a solution of DMSO (9.0 mL, 126 mmol) in CH2Cl2 (20 mL) and a solution of Cbz-Leucinol (38.2 mmol) [8] in CH2Cl2 (27 mL). After 10 min stirring at -78 °C a solution of DiPEA (40 mL, 230 mmol) in CH2Cl2 (100 mL) was added dropwise, and stirring was continued at -78 °C for 30 min. After warming up the mixture to rt, it was quenched with H2O (13 mL) while severely stirring. Et2O (300 mL) was added to the mixture and the organic layer was then washed with KHSO4 (1.0 M, 2x100 mL). The water layer was extracted with Et2O (1x100 mL) and the two organic layers were combined, dried over Na2SO4, and concentrated under reduced pressure, yielding Cbz-Leucinal (3) as a yellow oil (10.0 g, quantitative yield). The crude product was almost pure (TLC analysis) and was directly used in the WittigHorner reaction. 
Ethyl methanesulfonate (4)
Ethanol (6.40 mL, 110 mmol) was dissolved in dry CH2Cl2 (400 mL) and cooled in an ice bath. N-methyl morpoline (22.0 mL, 200 mL) and methanesulfonyl chloride (7.70 mL, 100 mmol) were added and the mixture was stirred for 30 min. Then the ice bath was removed and the reaction was stirred overnight at room temperature. CH2Cl2 (200 mL) was added to the mixture and the organic layer was washed with an aqueous solution of KHSO4 (1.0 M, 2 x 200 mL) and water (1 x 200 mL), dried over MgSO4 and concentrated, resulting in ethyl methanesulfonate (10 g, 80 mmol, 81 %) as a colorless oil. Characterization data were in agreement with the literature.
[21]
Ethyl diethylphosphorylmethanesulfonate (5)
Ethyl methanesulfonate 4 (10 g, 80 mmol) was dissolved in dry THF (200 mL) and treated with a 2.5 Ϻ n-BuLi solution in hexanes (35 mL, 89 mmol) over 30 min at −78 °C. After 15 min, diethylchlorophosphate (6.5 mL, 45 mmol) was added and the solution was stirred for 30 min at −78 °C and allowed to stir for 1 hour at −50 °C. The mixture was concentrated, the residue was diluted with water (100 mL) and extracted with CH2Cl2 (3 x 120 mL). The combined organic layers were dried over MgSO4 and concentrated. Purification of the crude by silica column by petroleum ether:ethyl acetate (1:1) as eluents delivered 5 as a colorless oil (6.5 g, 25 mmol, 56%). Characterization data were in agreement with the literature.
[22]
Cbz-vsLeu-OEt (6)
A stirring mixture of Wittig-Horner reagent 5 (6.5 g, 25 mmol) and anhydrous THF (100 mL) was cooled at -78 °C under N2 atmosphere. A solution of n-Butyllithium in hexanes (2.5 M, 10.5 mL, 26.2 mmol) was added dropwise, and after 20 min Cbz-Leucinal (3) (7.5 g, 30 mmol) in anhydrous THF (25 mL) was slowly added. Stirring was continued for 45 min at -78 °C and overnight at rt. The reaction mixture was then concentrated in vacuo, quenched with H2O (450 mL) and extracted with CH2Cl2 (3 x 450 mL). The combined organic layers were dried over anhydrous MgSO4 and concentrated to afford the crude 6. Purification by silica gel chromatography (20% EtOAc in petroleum ether) yielded compound 6 as a yellowish oil (6.1 g, 17 mmol, 68% yield). 
Cbz-vsLeu-ONBu4 (7)
A solution of compound 6 (6.1 g, 17 mmol) and NBu4I (6.3 g, 17 mmol) in acetone (400 mL) was stirred overnight under reflux. The reaction mixture was then concentrated in vacuo and coevaporated with CHCl3 (3x50 mL), yielding compound 7 as a dense yellow oil (11.3 g ). TLC analysis showed that the crude product was pure enough for being used in the next step without further purification. 1 
Cbz-Leu-VSF (8)
To a solution of compound 7 (4.8 g, 7.2 mmol) in dry CH2Cl2 (170 mL) was added XtalFluor-M® (3.72 g, 15.3 mmol), under N2 atmosphere. A catalytic quantity of Et3N•3HF (59 µL, 360 µmol) was added to the mixture, which was stirred overnight under reflux. After destruction of residual XtalFluor-M® by addition of silica gel to the solution, the mixture was filtered and concentrated in vacuo. Purification by silica gel chromatography (eluent: CH2Cl2 / petroleum ether (2/1)), afforded peptido vinylsulfonyl fluoride 8 as a white solid (720 mg, 2.18 mmol, 30% yield). Mp = 120°C. 
HCl·H-Leu-VSF (9)
A stirred solution of compound 8 (75.8 mg, 0.23 mmol) in CH2Cl2 (2.3 mL) was put under N2 atmosphere. After addition of HBr in acetic acid (33% v/v, 1.4 mL) stirring was continued for 30 min at rt. Then the solvents were evaporated and the residue dissolved in H2O (3.5 mL). Dowex-Cl (2×8, 200 mg) was added and the solution was stirred for 5 min at rt. and then filtrated. The water layer was washed with EtOAc (2x3.5 mL), then concentrated in vacuo and coevaporated with toluene (3x5 mL), yielding HCl•HLeu-VSF (9) as a yellowish solid (53.7 mg, 0.23 mmol, quantitative yield). The crude 9 was used directly in the synthesis of 10 and 11.
Cbz-Leu3-VSF (10)
To HCl salt 9 (43.3 mg, 0.187 mmol) were subsequently added BOP (86.7 mg, 0.196 mmol), Cbz-Leu2-OH [9] (70.8 mg, 0.187 mmol), CH2Cl2 (5 mL), and DiPEA (69 µL, 0.393 mmol). The mixture was stirred overnight at rt under N2. During the reaction, the pH was monitored (pH indicator paper) and kept to approximately 9 by adding additional DiPEA, if necessary. After evaporation of the solvent, the residue was dissolved in EtOAc (15 mL) and was washed with KHSO4 (1.0 M, 3×10 mL), and brine (10 mL). The organic layer was dried over Na2SO4 and concentrated. Purification with silica gel column chromatography (eluent: 26% EtOAc in hexanes) afforded Cbz-Leu 
Cbz-Leu4-VSF (11)
Cbz-Leu3-OMe (550 mg, 1.0 mmol) [23] was dissolved in Tesser's base (12.5 mL, mixture of NaOH (2.0 M), MeOH and dioxane, in proportion 1:5:14 (v/v/v)). After the mixture was stirred overnight at rt, it was neutralized to pH 7 (pH indicator paper) with KHSO4 (1.0 M). The dioxane was evaporated in vacuo and the mixture was acidified to pH 2 (pH indicator paper) with KHSO4 (1.0 M). The water layer was extracted with EtOAc (2x30 mL). The organic layer was washed with H2O (50 mL) and with brine (40 mL), dried over anhydrous Na2SO4 and concentrated in vacuo, yielding Cbz-leu3-OH as a white solid (501 mg, 1.0 mmol, quantitative yield). Cbz-Leu3-OH was coupled to HCl·H-Leu-VSF (9) using the procedure described in the synthesis of 10. 
TFA.H-Thr-Val-NHMe (13)
To a solution of Boc-valine (5.4 g, 23 mmol) was in CH2Cl2 (140 ml) was added BOP (10.2 g, 23 mmol). DiPEA (8.8 ml, 50 mmol) and subsequently methylamine (18.8 ml, 37.5 mmol, 2.0 M in THF) were added. After 2 hours stirring at rt, the mixture was concentrated in vacuo. Ethyl acetate (400 mL) was added and washed two times with KHSO4 (1.0 M, 200 mL), two times with NaHCO3 (1.0 M, 200 mL) and with brine (100 mL). After drying over Na2SO4 and concentration in vacuo, column chromatography (ethyl acetate/hexane, 40/60) was performed to afford Boc-ValNHMe (12) as a white solid (3.6 g, 65%). Boc-Val-NHMe (0.7 g, 3.0 mmol) was dissolved in CH2Cl2 (14 ml) and TFA was added (14 ml). The solution as stirred at rt for a half hour after which the mixture was concentrated in vacuo and coevaporated with chloroform (3x 200 mL). To the crude TFA.H-Val-NHMe was added CH2Cl2 (20 ml), BOP (1.0 g, 3.24 mmol), DiPEA (1.1 ml, 6.5 mmol) and Boc-Thr-OH (0.7 g, 3.0 mmol). After stirring at rt for 18 hours, the solvent was evaporated and KHSO4 (1.0 M, 250 mL) was added. After extraction with ethyl acetate (3x 100 mL), the organic layers were combined, dried over Na2SO4 and concentrated in vacuo. Crystallization from ethyl acetate afforded Boc-Thr-Val-NHMe (12) as a white solid (346 mg, 32%). , 2H, CH2CH(CH3)2), 1.47 (m, 1H, CH(CH3)2),  3.21 (m, 1H, SO2NCH) 
Proteasome Enzymatic Assays for IC50 Determination
Enzyme activity was determined by monitoring the hydrolysis of the fluorogenic substrate Suc-LLVY-AMC for 1 hour at room temperature. Fluorescence was measured at λexc = 360, λem = 460 nm. Point-measurements were performed with a 1 hour incubation of the enzyme with the inhibitors prior to substrate addition. MG132 was used as reference inhibitor (included in the assay kit). The enzyme solution (25 nM) was prepared by dilution of the supplied 20S proteasome (1 mg/mL) in VIVA buffer. A 10 µM stock solution of the substrate was made by dissolving Suc-LLVY-AMC (500 µg) in DMSO, which was diluted with VIVA buffer resulting in a 1.0 mM substrate solution. For the inhibitor stock solution (500 µM), the inhibitor (1.0 mg) was dissolved in DMSO. DMSO was used for the inhibitor dilutions. In a typical assay to each well was added enzyme solution (5 µL), inhibitor solution (4 µL), substrate solution (5 ul) and buffer (36 uL). Final concentrations in the wells were: enzyme: 2.5 nM; substrate: 10 mM; inhibitor: 0.4, 2, 10, 50, 100, 200, 400, 800, 1600 and 8000 nM. For the no inhibitor controls DMSO was added instead of inhibitor solution, thereby maintaining a final concentration of 9% DMSO per well. The assays were performed in triplicate. The inhibitory activities of compounds were expressed as IC50 values. The values were obtained by plotting the percentage of enzymatic activity against the logarithm of the inhibitor concentrations and fitting the experimental data to the equation % Residual Activity = 100/(1+10^((LogIC50-Log c (inhibitor))*HillSlope))) using GraphPad Prism software.
